Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.
European premenopausal women
LIBERTY
Uterine fibroids
heavy menstrual bleeding
relugolix combination therapy
Journal
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
ISSN: 1473-0766
Titre abrégé: Gynecol Endocrinol
Pays: England
ID NLM: 8807913
Informations de publication
Date de publication:
17 Aug 2023
17 Aug 2023
Historique:
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
27
8
2023
Statut:
ppublish
Résumé
In the 24-week, phase 3 LIBERTY 1 (L1) and LIBERTY 2 (L2) trials, relugolix combination therapy (relugolix-CT (relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg)) reduced uterine fibroid (UF)-associated symptoms. This Premenopausal women (aged 18-50 years) with UF-associated heavy menstrual bleeding (HMB) were randomized 1:1:1 in L1 ( In European women from L1/L2 ( In European women with UF and HMB, once-daily relugolix-CT vs. placebo improved UF-associated symptoms and preserved BMD.
Identifiants
pubmed: 37634528
doi: 10.1080/09513590.2023.2249107
doi:
Substances chimiques
relugolix
0
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
Langues
eng
Sous-ensembles de citation
IM